Introduction
Negative selection in thymus does represent an imperfect process and thus self-reacting T cell clones do escape central tolerance. Therefore, to keep these potential dangerous selfreactive T cells in check, a multitude of peripheral tolerance mechanisms exist. Dominant tolerance exerted by CD4+ regulatory T (T reg ) cells characterized by the expression of CD25 (IL2 receptor alpha) [1] does represent a major mechanism for immune homeostasis. A major breakthrough in the under-
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Summary
Adoptive transfer in animal models clearly indicate an essential role of CD4+ CD25+ FOXP3+ regulatory T (T reg ) cells in prevention and treatment of autoimmune and graft-versus-host disease. Thus, T reg cell therapies and development of drugs that specifically enhance T reg cell function and development represent promising tools to establish dominant tolerance. So far, lack of specific markers to differentiate human T reg cells from activated CD4+ CD25+ effector T cells, which also express FOXP3 at different levels, hampered such an approach. Recent identification of the orphan receptor glycoprotein-A repetitions predominant (GARP or LRRC32) as T reg cell-specific key molecule that dominantly controls FOXP3 via a positive feedback loop opens up new perspectives for molecular and cellular therapies. This brief review focuses on the role of GARP as a safeguard of a complex regulatory network of human T reg cells and its implications for regulatory T cell therapies in autoimmunity and graft-versus-host disease. standing of this peculiar subpopulation of CD4+ T cells was the identification of the forkhead transcription factor FOXP3 that is essential for their development and function [2] [3] [4] . The roles of FOXP3 and T reg cells are compellingly demonstrated by the natural loss-of-function, leading to the development of a fatal autoimmune lymphoproliferative disorder in man (IPEX, immunodysregulation, polyendocrinopathy, and enteropathy, X-linked) and mice (scurfy) [5] . Despite advances since the identification of FOXP3 for understanding T reg cell lineage, commitment and function differences between mice and man have become apparent [6] . Contrary to murine T reg cells, which are expressing FOXP3 as lineage-specific marker, consensus has now been reached that T cell receptor (TCR) stimulation of human nonregulatory CD4+ CD25-T h cells does induce FOXP3 expression without interfering with the expression of effector cytokines like IL2 and IFNγ or the acquisition of suppressor function [7] [8] [9] [10] . Moreover, even antigen-specific T h lines and clones can express FOXP3 to different extends [11] [12] [13] [14] [15] . With that, FOXP3 does not represent a bona fide marker of human T reg cells, suggesting the existence of a T reg cell-specific marker and/or higher-order regulatory networks to explain the qualitative and quantitative differences of FOXP3 expression of human T reg compared to conventional T h cells [16, 17] .
GARP Controls FOXP3 via a Positive Feedback Loop
The question of T reg cell-specific control mechanisms has been answered only recently with the identification of the orphan receptor glycoprotein-A repetitions predominant (GARP or LRRC32). GARP does represent a T reg cell-specific molecule that dominantly controls FOXP3 via a positive feedback loop (see below) [13, 18, 19] . T reg cell-specific expression of GARP has been further confirmed at the DNA level with the identification of a hypomethylated region in intron 1 together with two differentially methylated regions with enhancer function in human T reg cells [20] . Thus, lineage-directing transcription of GARP in T reg cells is based most likely on differential accessibility of the locus similar to what has been described for FOXP3 [15, 21] . The identification of GARP was enabled by differential gene expression analysis of TCR stimulated CD4+ CD25+ T reg cells compared to their CD4+ CD25-T h cell counterparts (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE13017) as TCR stimulation represents the prerequisite to activate their mutually exclusive functions. The functional contribution of GARP to the genetic program and phenotype of T reg cells was elucidated by ectopic overexpression in human alloantigen-specific T h cells and downregulation of GARP in human alloantigen-specific T reg cells. Retroviral overexpression of GARP in T h cells led to an efficient and stable re-programming of effector T towards T reg cells. This was associated with induction of constitutive expression of FOXP3, the β-galactoside binding protein LGALS3, the cystein-endoprotease LGMN, and an extended T reg cell signature similar to T reg cells [13] . Interestingly, LGALS3, recently identified FOXP3-dependent gene [11] , and LGMN do represent minor constituents of this feedback loop as they enhance GARP and FOXP3 expression following TCR activation.
LGALS represents an interesting regulator of anergy as it has been shown to directly interfere with TCR proximal signaling in human T cells [22] . Furthermore, FOXP3 induction via ectopic expression of LGALS3 depends on an intact serine-6 CK1 phosphorylation site [13] , whereas kinase inhibition of CK1 in T reg cells downregulates FOXP3 expression ( fig. 1 ). The result of the GARP-dependent re-programming process is established only after some rounds of antigen-specific TCR-(re-)stimulation. Surprisingly, GARP was more efficient, and the regulatory phenotype induced was stable compared to the overexpression of FOXP3. The final outcome of this complex transcriptional re-programming/ transdifferentiation of effector T h cells towards T reg cells was obvious as most of the T reg cell signature genes showed a sustained high level of expression and induction of effector cytokines was lost [13, 18] . Fig. 1 . CK1 inhibition affects FOXP3 expression in human T reg cells, suggesting the potential use of small molecules to interfere with T reg cell functions. Human alloantigen-specific T reg cells were pretreated over night with lactose that impairs the lectin binding function of LGALS3 [11] , CK1 kinase inhibitor (D4476, TOCRIS bioscience, Bristol, UK), and solvent control (DMSO) or irrelevant kinase inhibitors (PD98059 = MAP kinase inhibitor; SB202190 = p38 kinase inhibitor) and analyzed for intracellular FOXP3 as described [13] .
Probst-Kepper/Kröger/Garritsen/Buer Contrary, downregulation of GARP in human T reg cells, achieved by lentiviral transduction of specific small interfering RNA (siRNA), significantly impaired suppressor function and FOXP3 expression. This was associated with impaired induction of CD83 and CD27, both representing known FOXP3-regulating receptors [13, 23, 24] . Strikingly, lentiviral downregulation of FOXP3 with specific siRNA in T reg cells resulted in similar phenotypic changes and affected induction of GARP, CD83, and CD27. Therefore, a GARP-FOXP3-positive feedback loop in human T reg cells and a close interrelation with other FOXP3-regulating cell surface receptor systems was compellingly established. With that, speculations on a higher-order regulatory network and the necessity on a new molecular definition of human T reg cells [16, 17] reached a robust conceptual framework ( fig. 2) . Moreover, as TGFβ-induced T reg cells do not upregulate GARP, lack of GARP might explain the only transient and partial phenotype of TGFβ1-induced regulatory T h cells [10] , corroborating the need for a safeguard of FOXP3 expression and maintenance of the regulatory program. In sum, GARP is a key receptor controlling FOXP3 in T reg cells following TCR activation in a positive feedback loop, representing a promising new system for the therapeutic manipulation of T cells in human immune diseases ( fig. 3 ).
Future Directions of T reg Cell Therapies in View of GARP
Because of the encouraging results of adoptive transfer showing an essential role of CD4+ CD25+ FOXP3+ T reg cells in prevention and treatment of autoimmune [25] [26] [27] and graftversus-host disease (GvHD) [28] [29] [30] in animal models, first clinical trials have been started with CD4+ CD25+ T cells in humans [31, 32] . These trials should also provide insights into the potential effects of T reg cell therapies on the graftversus-leukemia effect, which is linked in part to GvHD [33] . But keeping in mind the difficulties to achieve pure T reg cell First of all, FOXP3 is expressed ab initio in T reg cells, because of difference in the accessibility of the FOXP3 locus [15, 21] , whereas it is induced with delay in T h cells following TCR stimulation. Lineage-restricted induction of GARP due also to selective hypomethylation of the locus in T reg cells [20] (indicated by lack of black dots) initiates a positive feedback loop that enhances and maintains high levels of FOXP3. This regulatory network is associated with redundant GARP/FOXP3-enhancing molecules, e.g. the β-galactoside-binding protein LGALS3, which also reveals lineagespecific differences of DNA methylation [20] , the endoprotease LGMN, receptor CD27 and CD83 suggesting a higher-order regulatory network [13] . preparations with using CD4+ CD25+ as surrogate marker of human T reg cells [34] , more reliable surface markers to exclude potential hazardous T h cell contaminations from T reg cell preparations have to be used. Such markers should be lineagespecific and indicators of proper regulatory function. GARP fulfills these demands as lineage-specific T reg marker that is responsible for maintenance of the regulatory program ( fig.  3 ). Concerning the limitations of T reg cell availability and the dominant role of GARP leading to stable FOXP3 expression and regulatory function in terminal differentiated alloantigenspecific T h cells [13] , genetically engineering disease-associated T h cells would represent an attractive alternative ( fig. 3 ).
Clinical Application of T reg Cells
In order to facilitate the transformation of research-based cell cultures and processes into clinical good manufacturing practice (GMP) procedures which are required for clinical application, a number of hurdles have to be taken. A strict standardization of the production is one of the most important parameters. Minimizing risks of contamination, especially microbial contamination during the cultivation process, is another important prerequisite for clinical application. Therefore, the clinical acceptance will be greatly improved with cell-cultivating systems which are modular closed systems and easy to use.
As we described in the first part of this review, T reg cells represent a critical component of the immune regulatory system. Through availability of specific antibodies and improved understanding of functional and genetic differentiation of T reg cells, we are now able to better define these T cells and standardize their isolation and quality control ( fig. 3 ). An important point still represents the limited quantity of T reg cells, representing a rare subset of CD4+ T cells estimated to be 2-4% or even lower, concerning proper gating to sort pure T reg cells [35] [36] [37] . Thus, ex vivo expansion is necessary but hindered by the fact that T reg cells replicate slowly in comparison to conventional T h cells [38] . In other words, if a batch of T reg cells is contaminated with other T h cells, these will in the end overgrow the T reg cell population, necessitating a re-purification step ( fig. 3 ). This problem has been noticed with most surface markers of human T reg cells (table 1) . Therefore, combinations of separate markers for primary enrichment of T reg cells ex vivo (e.g. CD4+ CD25+ CD127 lo [39] ) and later re-purification using other markers like GARP or other molecules differentially expressed on T reg cells (table 1) seems to be the future concept to get more pure T reg preparations [38] .
In the research situation most of the isolation procedures were performed using FACS sorting, a cell sorting methodology based upon physical properties of the cellular elements and use of fluorescently labelled antibodies against specific cellular membrane receptors [37] , which is time consuming. Thus, Riley et al. [31] stated the cumbersome FACS isolation Fig. 3 . Adoptive T reg cell therapy -perspectives. Based on the isolation of either CD4+ CD25-/int/+ T h cells or CD4+ CD25 hi T reg cells, two different strategies exist for adoptive regulatory T cell applications. i) Isolation of antigenspecific CD4+ T h cells from different disease settings (e.g. GvHD or autoimmunity) with the use of 'classical' antigen-specific stimulation/cloning procedures or by tretramer/ multimer separation [15] , and re-programming/transdifferentiation of these diseaseassociated effector towards T reg cells via genetic engineering with GARP as described for alloantigen-specific T h cells [13] . ii) Isolation of T reg cells and their preferable antigen-specific expansions with the need for re-isolation to exclude potential harmful antigen-specific T h cells included in the preparation be means of T reg cell-specific marker(s), including e.g. GARP or the recently described strategy of using CD121 (IL1R), recently identified as FOXP3-dependend molecule [11] , and LAP as T reg markers [19, 38, 48] (table 1) .
of this infrequent cell type by the words 'take a billion or so and call me in the morning'. Yet there is another important point with respect to contamination. FACS sorting is a relative open system with numerous porte d'entrées for microorganisms. This problem gets even greater concerning the need for several separation steps for enrichment and re-purification of antigen-specific T reg cells for cellular therapies, discussed above. In conclusion it will be difficult to obtain sufficient T reg cells under GMP conditions using this approach.
Modern cytapheresis procedures are the basis for harvesting sufficient numbers of mononuclear cells (10 10 -10 11 ) within an acceptable amount of time. This is not only possible for healthy donors but can be achieved with patients as well [40] [41] [42] . The collected mononuclear cells are harvested under the same conditions as classical blood products such as thrombocytapheresis products and are suitable for further processing in GMP facilities.
Novel immunomagnetic techniques in combination with specific antibodies enable the rapid isolation of cells in cell culture bags. This approach enables isolation and cultivation of a large amount of T reg cells in a GMP setting and therefore facilitates the clinical applicability of these cells [39, 43] . This approach also includes the possibility of ex vivo generation of human alloantigen-specific T reg cells at the step of in vitro expansion by means of antigen-specific stimulation with the use of a primary enrichment and a second re-purification step including GARP and other potential markers of T reg cells (table 1) [39] . Further protocols enable the ex vivo expansion of antigen-specific T h cells and genetic modifications of these cells [13, 44] . Although attractive, these approaches however are still rarely found in clinical settings.
Other approaches result from the better understanding of the T reg cells and try to modify T reg cells responses pharmacologically, for example by using antibodies, cytokines, or small molecules [45] (fig. 1 ).
Combining the knowledge we have on T reg cells with efficient medical devices for harvesting (apheresis) and isolation (e.g. clinimacs) we are gradually coming in a position in which we will see clinical applications starting.
Concluding Remarks
The identification of GARP as lineage-restricted key receptor of human T reg cells and the characterization of a GARP-FOXP3 positive feedback loop as essential component for the maintenance of the regulatory phenotype does provide a conceptual framework for a new molecular definition of the regulatory program. Open questions remaining include the signal transduction pathway of GARP and the potential ligand. Development of potential GARP-ligand mimetics to enhance regulatory functions in vivo should take into account expression and function of GARP in platelets [46, 47] . In-depth elucidation of the GARP-FOXP3 regulatory system does represent a major challenge for the future and opens up the possibility for generation of antigen-specific T reg cells for adoptive cellular therapies ( fig. 3 ) and identification of new molecular targets to develop new strategies to enhance T reg cells in autoimmune diseases and transplantation.
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